{"id":"NCT01992523","sponsor":"David Antoniucci","briefTitle":"Mojito Study (Mashed Or Just Integral Pill of TicagrelOr ? )","officialTitle":"Mojito Study (Mashed Or Just Integral Pill of TicagrelOr ? )","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-11","primaryCompletion":"2014-03","completion":"2014-04","firstPosted":"2013-11-25","resultsPosted":"2015-03-17","lastUpdate":"2015-03-17"},"enrollment":82,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Acute Coronary Syndrome","Adverse Reaction to Antiplatelet Agent"],"interventions":[{"type":"DRUG","name":"Ticagrelor mashed pills","otherNames":[]},{"type":"DRUG","name":"Ticagrelor integral pills","otherNames":[]}],"arms":[{"label":"Ticagrelor mashed pills","type":"EXPERIMENTAL"},{"label":"Ticagrelor integral pills","type":"ACTIVE_COMPARATOR"}],"summary":"The aim of the Mashed Or Just Integral pill of TicagrelOr (MOJITO) study is to evaluate the superiority of Ticagrelor 180 mg LD mashed pill versus Ticagrelor 180 mg LD integral pill both orally administrated in decreasing residual platelet reactivity 1 hour after the administration among 70 patients with STEMI (ST segment elevation myocardial infarction) undergoing PPCI (primary percutaneous coronary intervention) with bivalirudin monotherapy.","primaryOutcome":{"measure":"Residual Platelet Reactivity","timeFrame":"1 hour","effectByArm":[{"arm":"Ticagrelor Mashed Pills","deltaMin":168,"sd":null},{"arm":"Ticagrelor Integral Pills","deltaMin":252,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.006"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":16},"locations":{"siteCount":2,"countries":["Greece","Italy"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":41},"commonTop":["Dyspnea","Serum creatinine increase","TIMI minor bleeding (TIMI criteria)","Ventricular pauses >= 3 sec"]}}